Nanobiotix (NASDAQ:NBTX) Shares Gap Down – Should You Sell?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s stock price gapped down prior to trading on Monday . The stock had previously closed at $35.12, but opened at $31.93. Nanobiotix shares last traded at $31.9330, with a volume of 28,232 shares traded.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on NBTX. UBS Group raised their price target on Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, May 1st. Guggenheim raised their price target on Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, April 2nd. TD Cowen reissued a “buy” rating on shares of Nanobiotix in a research note on Thursday, March 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research note on Tuesday, April 21st. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Nanobiotix has an average rating of “Moderate Buy” and a consensus price target of $26.67.

Nanobiotix Stock Up 20.4%

The business has a fifty day moving average price of $32.23 and a 200 day moving average price of $25.41.

Nanobiotix (NASDAQ:NBTX) last released its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) EPS for the quarter. The firm had revenue of $3.42 million during the quarter. As a group, equities research analysts anticipate that Nanobiotix S.A. – Sponsored ADR will post 0.53 earnings per share for the current year.

Institutional Investors Weigh In On Nanobiotix

Several hedge funds have recently modified their holdings of NBTX. Millennium Management LLC purchased a new stake in shares of Nanobiotix during the 4th quarter valued at about $390,000. Marshall Wace LLP purchased a new stake in Nanobiotix during the 4th quarter worth approximately $220,000. Optiver Holding B.V. purchased a new stake in Nanobiotix during the 3rd quarter worth approximately $101,000. Finally, Royal Bank of Canada increased its holdings in Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after purchasing an additional 2,500 shares during the last quarter. 38.81% of the stock is currently owned by hedge funds and other institutional investors.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.